Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) Income towards Parent Company: 2012-2023

Historic Income towards Parent Company for RedHill Biopharma (RDHL) over the last 11 years, with Jun 2023 value amounting to $58.9 million.

  • RedHill Biopharma's Income towards Parent Company rose 231.03% to $58.9 million in Q2 2023 from the same period last year, while for Jun 2023 it was -$40.0 million, marking a year-over-year increase of 75.62%. This contributed to the annual value of -$8.3 million for FY2024, which is 134.57% down from last year.
  • Latest data reveals that RedHill Biopharma reported Income towards Parent Company of $58.9 million as of Q2 2023, which was up 844.05% from -$7.9 million recorded in Q1 2023.
  • In the past 5 years, RedHill Biopharma's Income towards Parent Company ranged from a high of $58.9 million in Q2 2023 and a low of -$145.2 million during Q4 2021.
  • Moreover, its 3-year median value for Income towards Parent Company was $2.4 million (2022), whereas its average is -$17.0 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first spiked by 232.46% in 2020, then slumped by 469.08% in 2021.
  • RedHill Biopharma's Income towards Parent Company (Quarterly) stood at $11.8 million in 2019, then surged by 232.46% to $39.4 million in 2020, then tumbled by 469.08% to -$145.2 million in 2021, then soared by 52.14% to -$69.5 million in 2022, then surged by 231.03% to $58.9 million in 2023.
  • Its Income towards Parent Company stands at $58.9 million for Q2 2023, versus -$7.9 million for Q1 2023 and -$69.5 million for Q4 2022.